M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn Pharmaceutical Technologyargenx has entered into a definitive agreement to acquire Forte Biosciences for approximately $2.2bn in total equity value.Immunology & InflammationRead full story pharminent July 28, 2026 (Last updated: July 28, 2026) Pharmaceutical Technology argenx has entered into a definitive agreement to acquire Forte Biosciences for approximately $2.2bn in total equity value. Immunology & Inflammation Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: AstraZeneca Says Drug Pricing Is ‘Evolving’ in Response to Trump’s Most-Favored-Nation PolicyNext: GSK Unveils Three-Year Restructuring to Fund Late-Stage R&D Ahead of Patent Cliff Related Stories M&A / Deals Argenx deepens immuno expertise with $2.2B Forte Biosciences buy pharminent July 27, 2026 M&A / Deals Repligen builds in cell therapy with $1.5bn BioLife takeover pharminent July 22, 2026 M&A / Deals Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics pharminent July 20, 2026
